web analytics
Drug Formulation Development | Preclinical Drug Development | Pharmaceutical Formulation

Drug Formulation Development

For inquiries, please contact us here



Early Phase Drug Formulation Development Specialty

Velesco’s preclinical drug development process will ensure exposure in toxicology studies.


             check 3 25pixelSmall scale, customized experiments 

             check 3 25pixelOptimize exposure 

             check 3 25pixelPreserve your limited clinical supply

             check 3 25pixelSolutions, suspensions, gels, encapsulation, creams, etc


Velesco’s expertise in developing pharmaceutical formulations for non-clinical toxicology studies can help optimize exposure. We specialize in small scale, customized experiments that will preserve your limited compound supply. Velesco’s pharmaceutical formulation, be it a binary solution, or a complicated SEDDS (self-emulsifying drug delivery systems) mixture, will be tailored to your molecule, dose range, and drug delivery route.  Ideally, we develop an uncomplicated drug formulation that is easy to replicate and can be transferred with ease. 


Velesco's preclinical development of drug formulations encompass gels, solutions, and suspensions for oral, IV, or topical dosing.


We can be your partners in your pharmaceutical development, meeting very aggressive timelines by working closely with your toxicologist.  Your drug formulation will achieve the concentration requirements without inducing additional adverse toxic effects.  Velesco's contract manufacturing pharmaceutical experts have prepared single formulations which are suitable for multiple routes of administration, can be carried forward into later toxicology studies and can even transition into clinical studies.


Velesco’s clinical pharmaceutical formulation development will be suitable for manufacture and for delivering your drug to the patient.


Velesco Pharma's experience in developing clinical drug formulations ranges from simple, early phase dosage forms to more complicated, later phase formulations.


Velesco specializes in softgel capsule, suspension, and other non-sterile liquid pharmaceutical formulations, which can be developed for a wide variety of compounds.


Velesco's experts approach our drug formulation projects by evaluating the characteristics of the molecule, creating a formulation that is scalable, elegant, and utilizes widely available excipients.


In conjunction with our analytical services department, we can analyze your formulation by HPLC. Our HPLC method validation determines the chemical and physical stability of your pharmaceutical formulation.  If you don't have an HPLC method appropriate for this use, our experienced team can develop a "fit for purpose" method, or we can determine physical stability visually.


Our case studies for drug formulation development challenges give a brief taste of the value our pharmaceutical formulation services can bring to your project.


  • Toxicology formulations
  • Human formulations
  • Solubility assessment in a range of vehicles
  • Hard gelatin capsules
  • Soft gelatin capsules
  • Creams
  • Gels
  • Oral and topical liquids
  • Small and large volume parenterals drugs

  BOAA Velesco 020





Learn more about how Velesco can help advance your pharmaceutical development.

For inquiries, please contact us here



Privacy Policy

News and Events

Pace® Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services

Read the Press Release!

Dave Barnes, Ph.D. CEO/CSO is a featured speaker for the webinar Topical Formulation: Selection of Excipients and Better Process Understanding for Success in Commercial Manufacturing. Webinar recording available now.

View Recording!

Newly Acquired DEA Analytical Laboratory License. We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Roundtable: M&A trends in CDMO - Molecule to Market

New Velesco Pharma clinical manufacturing facility begins operations.

Read the press release here.

Lisa Crandall, MS, and Peter Angus, PhD, spoke with Pharmaceutical Technology about the best practices in stability testing.

Read the interview here.

Velesco has expanded our analytical facilities in a new Wixom, Michigan location with the help of the Bank of Ann Arbor Technology Industry Group.

Read the press release here.

CEO Dave Barnes has been published in a new Pharmoutsourcing article on Clinical Trial Materials and Manufacturing!

1 new job postings! Careers

Velesco's work published

Formulation Development & Manufacturing:
Using a Single Provider Reduces Costs & Risk
Read it here.

Follow Velesco

LinkedIn IN Icon 25px Google+ Follow VelescoPharma on Twitter FB FindUsOnFacebook 100